中国医药科学Issue(1)：100-102,3.
吉非替尼与厄洛替尼治疗非小细胞肺癌临床疗效比较及药物经济学评价
Clinical effect and pharmacoeconomics of gefitinib and erlotinib in advanced non-small-cell lung cancer
翁秀连1
作者信息
- 1. 福建省肿瘤医院药剂科，福建福州350001
- 折叠
摘要
Abstract
Objective To explore the clinical effect and pharmacoeconomics of gefitinib and erlotinib in advanced non-small-cell lung cancer. Methods 72 cases of patients with NSCLC were divided into experiment group and control group. The experiment group(38 cases) were treated by Gefitinib, the control group(34 cases) were treated by Erlotinib. The clinical effects, complication and pharmacoeconomics were compared for the two groups. Results There was no significant difference on the effective rate and clinical control rate for the two groups(P>0.05);There was no significant difference on the time to tumor progression and one year survival rate for the two groups(P>0.05);There was no significant difference on the complication and severity for the two groups(P>0.05);The treatment costs and clinical effects for the experiment group were lower than the control group(P < 0.05). Conclusion It has the similar clinical effects by gefitinib and erlotinib, gefitinib has good economy applicable.关键词
吉非替尼/厄洛替尼/非小细胞肺癌/疗效/药物经济学Key words
Gefitinib/Erlotinib/Non-small-cell lung cancer/Clinical effects/Pharmacoeconomics分类
医药卫生引用本文复制引用
翁秀连..吉非替尼与厄洛替尼治疗非小细胞肺癌临床疗效比较及药物经济学评价[J].中国医药科学,2015,(1):100-102,3.
